Spanish medtech "cartel" cites market forces in its defence
This article was originally published in Clinica
Pending confirmation of a prospective appeal by four companies recently found guilty of price-fixing in tenders for radiopharmaceutical products (see full story, published October 6), the judgement report provides an interesting insight into this market. Does the case in fact illustrate the market pressures faced by industry? observers will wonder.
You may also be interested in...
Device Week, 4 December 2020 – MedWatch Question About Third-Party Servicers Slides Under Industry's Radar
On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency.
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.